Outline of the protocol. Participants with type 2 diabetes were randomized to undergo either 12 weeks of aerobic training (“Training”) or to undergo treatment with semaglutide (“Semaglutide and training”) for 20 weeks before entering the 12 weeks training regimen while continuing semaglutide treatment. Before and after each intervention (“Semaglutide,” “Semaglutide and training,” and “Training”), 2 experimental days were carried out. The primary outcome was a change in β-cell secretory function assessed by a hyperglycemic (20 and 30 mM) clamp. Semaglutide was taken once weekly and escalated according to the guidelines. The follow-up 2-stepped hyperglycemic clamp (experimental day 1) was always performed 40 to 48 hours after the last bout of exercise and 7 days after the last dosage of semaglutide. The next dosage of semaglutide was postponed to completion of the oral glucose tolerance test. In weeks 1 and 12 of the training intervention, the participants performed a 45-minute exercise test at 70% of VO_2max with blood sampling to investigate adaptations and interactions to the glucoregulatory and inflammatory response. The training was performed on a cycle ergometer 3 times weekly at an average intensity of 75% of the heart rate reserve (see Appendix (24)).